The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.85
Bid: 48.60
Ask: 48.70
Change: 1.60 (3.39%)
Spread: 0.10 (0.206%)
Open: 47.55
High: 49.55
Low: 47.55
Prev. Close: 47.25
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - IP Group Plc

18 Jul 2017 11:45

RNS Number : 3870L
JPMorgan Securities Plc
18 July 2017
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-

SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

IP Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Corporate Broker and Financial Advisor to Touchstone Innovations Plc

(d) Date dealing undertaken:

17 July 2017

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes,

Touchstone Innovations Plc

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

(GBP)

 

Lowest price per unit paid/received

(GBP)

 

Ordinary Shares

 

Purchases

 

Sales

16,670

 

3,670

1.3880

 

1.3850

1.3610

 

1.3700

 

 

 

(b) Cash-settled derivative transactions

 

 

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(GBP)

Ordinary Shares

Equity Swaps

 

Long

 

 

 

Short

530

1,706

1,350

 

1,460

451

5,651

327

6,268

1.3699

1.3825

1.3843

 

1.3695

1.3700

1.3713

1.3720

1.3754

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBP)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(GBP)

Ordinary Shares

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(GBP)

Ordinary Shares

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable) (GBP)

 

 

 

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

18 July 2017

Contact name:

Evangelos Galiatsatos

Telephone number:

020 7742 6148

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERGGUWCMUPMGUR
Date   Source Headline
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results
3rd Aug 20207:00 amRNSNanopore partners with govt on covid-19 test
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
29th Jul 20209:45 amRNSHolding(s) in Company
28th Jul 20202:44 pmRNSNotice of Results
14th Jul 20201:29 pmRNSIP Group sells 9.16m shares in Ceres Power
14th Jul 20207:00 amRNSResult of secondary placing in Ceres Power
13th Jul 20205:11 pmRNSProposed secondary placing in Ceres Power Holdings
6th Jul 202012:02 pmRNSPrice Monitoring Extension
6th Jul 20207:00 amRNSAppoints Prof. Clark Chair of ESG Ethics Committee
3rd Jul 202012:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.